文献速递肺栓塞与肺血管病肺结节与肺癌

简化肺栓塞严重指数评分在活动性癌症合并肺栓塞患者中的识别价值:COMMAND VTE注册研究

Usefulness of Simplified Pulmonary Embolism Severity Index Score for Identification of Patients With Low-Risk Pulmonary Embolism and Active Cancer: From the COMMAND VTE Registry.
PubMed 文献 · Chest · 2019-10-09

基于COMMAND VTE多中心注册研究中368例活动性癌症合并肺栓塞患者,比较sPESI评分=1与≥2组的30天临床结局。sPESI=1组30天全因死亡率和PE相关死亡率均显著低于≥2组,但全因死亡率仍较高(主要死于癌症),且两组复发VTE和大出血风险无显著差异,提示需密切随访。

要点

  • 活动性癌症合并PE患者中,sPESI=1组30天全因死亡率6.3%,显著低于≥2组的13.1%。
  • sPESI=1组PE相关死亡率仅0.7%,但仍需警惕癌症相关死亡及出血复发风险。
  • sPESI评分可用于活动性癌症合并PE患者的低危识别,但需结合癌症情况综合评估。

核心结论

  • 在活动性癌症合并PE患者中,sPESI评分=1者30天全因死亡率和PE相关死亡率均低于sPESI≥2者。
  • sPESI=1组全因死亡率仍较高,主要死因为癌症,且复发VTE和大出血风险相对较高,需密切随访。

研究设计与样本

  • COMMAND VTE Registry为多中心注册研究,连续纳入急性症状性VTE患者。
  • 本研究纳入368例活动性癌症合并PE患者,比较sPESI=1组与sPESI≥2组的30天临床结局。

主要发现

  • 整体30天死亡37例(10%)。
  • sPESI=1组与≥2组的30天全因死亡率分别为6.3%与13.1%(log-rank P = .03)。
  • sPESI=1组与≥2组的30天PE相关死亡率分别为0.7%与3.9%(log-rank P = .046)。
  • sPESI=1组主要死因为癌症。
  • 两组30天复发VTE发生率分别为3.9%与5.6%(log-rank P = .46),大出血发生率分别为6.4%与4.5%(log-rank P = .45),均无显著差异。

关键数值与推荐

  • sPESI评分=1定义为低危组,≥2定义为非低危组。
  • sPESI=1组30天全因死亡6.3%、PE相关死亡0.7%、复发VTE 3.9%、大出血6.4%。
  • sPESI≥2组30天全因死亡13.1%、PE相关死亡3.9%、复发VTE 5.6%、大出血4.5%。

临床怎么用

  • 对活动性癌症合并PE患者,sPESI=1可辅助识别PE相关死亡风险极低者。
  • sPESI=1的活动性癌症合并PE患者仍需关注癌症相关死亡、复发VTE和大出血风险,应密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The simplified Pulmonary Embolism Severity Index (sPESI) score is a practical score for identification of patients with low-risk pulmonary embolism (PE), although it has not been applied in patients with active cancer. The current study aimed to evaluate the usefulness of the sPESI score in patients with PE and active cancer. METHODS: The COMMAND VTE Registry is a multicenter registry enrolling consecutive patients with acute symptomatic VTE. The current study population consisted of 368 patients with PE and active cancer. The 30-day clinical outcomes were compared between patients with sPESI score = 1 and patients with sPESI scores ≥ 2. RESULTS: Overall, 37 patients (10%) died during the 30 days after diagnosis. The cumulative 30-day incidences of mortality, and PE-related death, were lower in patients with sPESI score = 1 than in patients with sPESI scores ≥ 2 (6.3% vs 13.1%; log-rank P = .03; and 0.7% vs 3.9%; log-rank P = .046). Among patients with sPESI score = 1, the predominant cause of death was cancer. There were no significant differences in the cumulative 30-day incidence of recurrent VTE and major bleeding between the two groups (3.9% vs 5.6%; log-rank P = .46; and 6.4% vs 4.5%; log-rank P = .45). CONCLUSIONS: Among patients with PE and active cancer, patients with sPESI score = 1 had a lower 30-day mortality rate compared with patients with sPESI scores ≥ 2, and they showed very low PE-related mortality risk, although the overall mortality rate remained high because of cancer-related mortality. They also showed relatively high risks for recurrence and major bleeding, suggesting the need for careful follow-up. TRIAL REGISTRY: UMIN Clinical Trials Registry; No.: UMIN000021132; URL: http://www.umin.ac.jp/ctr/index.htm.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Yamashita Y, Morimoto T, Amano H, et al. Usefulness of Simplified Pulmonary Embolism Severity Index Score for Identification of Patients With Low-Risk Pulmonary Embolism and Active Cancer: From the COMMAND VTE Registry. Chest. 2019. PMID: 31605702. doi:10.1016/j.chest.2019.08.2206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。